Medication Persistence With Weekly Versus Daily Doses of Orally Administered Bisphosphonates
- 1 September 2006
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 12 (5), 522-528
- https://doi.org/10.4158/ep.12.5.522
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE StudyJournal of Bone and Mineral Research, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Efficacy and safety of ibandronate given by intravenous injection once every 3 monthsBone, 2004
- Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health CareCMAJ : Canadian Medical Association Journal, 2004
- Social Support and Patient Adherence to Medical Treatment: A Meta-Analysis.Health Psychology, 2004
- The impact of reducing dose frequency on health outcomesClinical Therapeutics, 2003
- Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: A retrospective, observational studyArthritis & Rheumatism, 2003
- Effects of Once-Daily and Twice-Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 DiabetesSouthern Medical Journal, 2002
- Determinants of long-term hormone replacement therapy and reasons for early discontinuationPublished by Ovid Technologies (Wolters Kluwer Health) ,2000
- Bisphosphonates in osteoporosis: recent clinical experienceExpert Opinion on Pharmacotherapy, 2000